IBDEI10J ; ; 01-FEB-2022
;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 01, 2022
Q:'DIFQR(358.3) F I=1:2 S X=$T(Q+I) Q:X="" S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E S @X=Y
Q Q
;;^UTILITY(U,$J,358.3,16475,1,3,0)
;;=3^Acute Promyelocytic Leukemia,In Remission
;;^UTILITY(U,$J,358.3,16475,1,4,0)
;;=4^C92.41
;;^UTILITY(U,$J,358.3,16475,2)
;;=^5001802
;;^UTILITY(U,$J,358.3,16476,0)
;;=C92.40^^61^775^20
;;^UTILITY(U,$J,358.3,16476,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,16476,1,3,0)
;;=3^Acute Promyelocytic Leukemia,Not in Remission
;;^UTILITY(U,$J,358.3,16476,1,4,0)
;;=4^C92.40
;;^UTILITY(U,$J,358.3,16476,2)
;;=^5001801
;;^UTILITY(U,$J,358.3,16477,0)
;;=D56.0^^61^775^21
;;^UTILITY(U,$J,358.3,16477,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,16477,1,3,0)
;;=3^Alpha Thalassemia
;;^UTILITY(U,$J,358.3,16477,1,4,0)
;;=4^D56.0
;;^UTILITY(U,$J,358.3,16477,2)
;;=^340494
;;^UTILITY(U,$J,358.3,16478,0)
;;=D63.1^^61^775^23
;;^UTILITY(U,$J,358.3,16478,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,16478,1,3,0)
;;=3^Anemia in Chronic Kidney Disease
;;^UTILITY(U,$J,358.3,16478,1,4,0)
;;=4^D63.1
;;^UTILITY(U,$J,358.3,16478,2)
;;=^332908
;;^UTILITY(U,$J,358.3,16479,0)
;;=D63.0^^61^775^24
;;^UTILITY(U,$J,358.3,16479,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,16479,1,3,0)
;;=3^Anemia in Neoplastic Disease
;;^UTILITY(U,$J,358.3,16479,1,4,0)
;;=4^D63.0
;;^UTILITY(U,$J,358.3,16479,2)
;;=^321978
;;^UTILITY(U,$J,358.3,16480,0)
;;=D63.8^^61^775^22
;;^UTILITY(U,$J,358.3,16480,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,16480,1,3,0)
;;=3^Anemia in Chronic Diseases Classified Elsewhere
;;^UTILITY(U,$J,358.3,16480,1,4,0)
;;=4^D63.8
;;^UTILITY(U,$J,358.3,16480,2)
;;=^5002343
;;^UTILITY(U,$J,358.3,16481,0)
;;=C22.3^^61^775^27
;;^UTILITY(U,$J,358.3,16481,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,16481,1,3,0)
;;=3^Angiosarcoma of Liver
;;^UTILITY(U,$J,358.3,16481,1,4,0)
;;=4^C22.3
;;^UTILITY(U,$J,358.3,16481,2)
;;=^5000936
;;^UTILITY(U,$J,358.3,16482,0)
;;=D61.9^^61^775^28
;;^UTILITY(U,$J,358.3,16482,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,16482,1,3,0)
;;=3^Aplastic Anemia,Unspec
;;^UTILITY(U,$J,358.3,16482,1,4,0)
;;=4^D61.9
;;^UTILITY(U,$J,358.3,16482,2)
;;=^5002342
;;^UTILITY(U,$J,358.3,16483,0)
;;=D56.1^^61^775^34
;;^UTILITY(U,$J,358.3,16483,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,16483,1,3,0)
;;=3^Beta Thalassemia
;;^UTILITY(U,$J,358.3,16483,1,4,0)
;;=4^D56.1
;;^UTILITY(U,$J,358.3,16483,2)
;;=^340495
;;^UTILITY(U,$J,358.3,16484,0)
;;=C83.79^^61^775^36
;;^UTILITY(U,$J,358.3,16484,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,16484,1,3,0)
;;=3^Burkitt Lymphoma,Extranodal/Solid Organ Sites
;;^UTILITY(U,$J,358.3,16484,1,4,0)
;;=4^C83.79
;;^UTILITY(U,$J,358.3,16484,2)
;;=^5001600
;;^UTILITY(U,$J,358.3,16485,0)
;;=C83.70^^61^775^37
;;^UTILITY(U,$J,358.3,16485,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,16485,1,3,0)
;;=3^Burkitt Lymphoma,Unspec Site
;;^UTILITY(U,$J,358.3,16485,1,4,0)
;;=4^C83.70
;;^UTILITY(U,$J,358.3,16485,2)
;;=^5001591
;;^UTILITY(U,$J,358.3,16486,0)
;;=D09.0^^61^775^44
;;^UTILITY(U,$J,358.3,16486,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,16486,1,3,0)
;;=3^Carcinoma in Situ of Bladder
;;^UTILITY(U,$J,358.3,16486,1,4,0)
;;=4^D09.0
;;^UTILITY(U,$J,358.3,16486,2)
;;=^267742
;;^UTILITY(U,$J,358.3,16487,0)
;;=D06.9^^61^775^45
;;^UTILITY(U,$J,358.3,16487,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,16487,1,3,0)
;;=3^Carcinoma in Situ of Cervix
;;^UTILITY(U,$J,358.3,16487,1,4,0)
;;=4^D06.9
--- Routine Detail --- with STRUCTURED ROUTINE LISTING ---[H[J[2J[HIBDEI10J 3762 printed Sep 23, 2025@19:35:22 Page 2
IBDEI10J ; ; 01-FEB-2022
+1 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 01, 2022
+2 if 'DIFQR(358.3)
QUIT
FOR I=1:2
SET X=$TEXT(Q+I)
if X=""
QUIT
SET Y=$EXTRACT($TEXT(Q+I+1),4,999)
SET X=$EXTRACT(X,4,999)
if $ASCII(Y)=126
SET I=I+1
SET Y=$EXTRACT(Y,2,999)_$EXTRACT($TEXT(Q+I+1),5,999)
if $ASCII(Y)=61
SET Y=$EXTRACT(Y,2,999)
XECUTE NO
IF '$TEST
SET @X=Y
Q QUIT
+1 ;;^UTILITY(U,$J,358.3,16475,1,3,0)
+2 ;;=3^Acute Promyelocytic Leukemia,In Remission
+3 ;;^UTILITY(U,$J,358.3,16475,1,4,0)
+4 ;;=4^C92.41
+5 ;;^UTILITY(U,$J,358.3,16475,2)
+6 ;;=^5001802
+7 ;;^UTILITY(U,$J,358.3,16476,0)
+8 ;;=C92.40^^61^775^20
+9 ;;^UTILITY(U,$J,358.3,16476,1,0)
+10 ;;=^358.31IA^4^2
+11 ;;^UTILITY(U,$J,358.3,16476,1,3,0)
+12 ;;=3^Acute Promyelocytic Leukemia,Not in Remission
+13 ;;^UTILITY(U,$J,358.3,16476,1,4,0)
+14 ;;=4^C92.40
+15 ;;^UTILITY(U,$J,358.3,16476,2)
+16 ;;=^5001801
+17 ;;^UTILITY(U,$J,358.3,16477,0)
+18 ;;=D56.0^^61^775^21
+19 ;;^UTILITY(U,$J,358.3,16477,1,0)
+20 ;;=^358.31IA^4^2
+21 ;;^UTILITY(U,$J,358.3,16477,1,3,0)
+22 ;;=3^Alpha Thalassemia
+23 ;;^UTILITY(U,$J,358.3,16477,1,4,0)
+24 ;;=4^D56.0
+25 ;;^UTILITY(U,$J,358.3,16477,2)
+26 ;;=^340494
+27 ;;^UTILITY(U,$J,358.3,16478,0)
+28 ;;=D63.1^^61^775^23
+29 ;;^UTILITY(U,$J,358.3,16478,1,0)
+30 ;;=^358.31IA^4^2
+31 ;;^UTILITY(U,$J,358.3,16478,1,3,0)
+32 ;;=3^Anemia in Chronic Kidney Disease
+33 ;;^UTILITY(U,$J,358.3,16478,1,4,0)
+34 ;;=4^D63.1
+35 ;;^UTILITY(U,$J,358.3,16478,2)
+36 ;;=^332908
+37 ;;^UTILITY(U,$J,358.3,16479,0)
+38 ;;=D63.0^^61^775^24
+39 ;;^UTILITY(U,$J,358.3,16479,1,0)
+40 ;;=^358.31IA^4^2
+41 ;;^UTILITY(U,$J,358.3,16479,1,3,0)
+42 ;;=3^Anemia in Neoplastic Disease
+43 ;;^UTILITY(U,$J,358.3,16479,1,4,0)
+44 ;;=4^D63.0
+45 ;;^UTILITY(U,$J,358.3,16479,2)
+46 ;;=^321978
+47 ;;^UTILITY(U,$J,358.3,16480,0)
+48 ;;=D63.8^^61^775^22
+49 ;;^UTILITY(U,$J,358.3,16480,1,0)
+50 ;;=^358.31IA^4^2
+51 ;;^UTILITY(U,$J,358.3,16480,1,3,0)
+52 ;;=3^Anemia in Chronic Diseases Classified Elsewhere
+53 ;;^UTILITY(U,$J,358.3,16480,1,4,0)
+54 ;;=4^D63.8
+55 ;;^UTILITY(U,$J,358.3,16480,2)
+56 ;;=^5002343
+57 ;;^UTILITY(U,$J,358.3,16481,0)
+58 ;;=C22.3^^61^775^27
+59 ;;^UTILITY(U,$J,358.3,16481,1,0)
+60 ;;=^358.31IA^4^2
+61 ;;^UTILITY(U,$J,358.3,16481,1,3,0)
+62 ;;=3^Angiosarcoma of Liver
+63 ;;^UTILITY(U,$J,358.3,16481,1,4,0)
+64 ;;=4^C22.3
+65 ;;^UTILITY(U,$J,358.3,16481,2)
+66 ;;=^5000936
+67 ;;^UTILITY(U,$J,358.3,16482,0)
+68 ;;=D61.9^^61^775^28
+69 ;;^UTILITY(U,$J,358.3,16482,1,0)
+70 ;;=^358.31IA^4^2
+71 ;;^UTILITY(U,$J,358.3,16482,1,3,0)
+72 ;;=3^Aplastic Anemia,Unspec
+73 ;;^UTILITY(U,$J,358.3,16482,1,4,0)
+74 ;;=4^D61.9
+75 ;;^UTILITY(U,$J,358.3,16482,2)
+76 ;;=^5002342
+77 ;;^UTILITY(U,$J,358.3,16483,0)
+78 ;;=D56.1^^61^775^34
+79 ;;^UTILITY(U,$J,358.3,16483,1,0)
+80 ;;=^358.31IA^4^2
+81 ;;^UTILITY(U,$J,358.3,16483,1,3,0)
+82 ;;=3^Beta Thalassemia
+83 ;;^UTILITY(U,$J,358.3,16483,1,4,0)
+84 ;;=4^D56.1
+85 ;;^UTILITY(U,$J,358.3,16483,2)
+86 ;;=^340495
+87 ;;^UTILITY(U,$J,358.3,16484,0)
+88 ;;=C83.79^^61^775^36
+89 ;;^UTILITY(U,$J,358.3,16484,1,0)
+90 ;;=^358.31IA^4^2
+91 ;;^UTILITY(U,$J,358.3,16484,1,3,0)
+92 ;;=3^Burkitt Lymphoma,Extranodal/Solid Organ Sites
+93 ;;^UTILITY(U,$J,358.3,16484,1,4,0)
+94 ;;=4^C83.79
+95 ;;^UTILITY(U,$J,358.3,16484,2)
+96 ;;=^5001600
+97 ;;^UTILITY(U,$J,358.3,16485,0)
+98 ;;=C83.70^^61^775^37
+99 ;;^UTILITY(U,$J,358.3,16485,1,0)
+100 ;;=^358.31IA^4^2
+101 ;;^UTILITY(U,$J,358.3,16485,1,3,0)
+102 ;;=3^Burkitt Lymphoma,Unspec Site
+103 ;;^UTILITY(U,$J,358.3,16485,1,4,0)
+104 ;;=4^C83.70
+105 ;;^UTILITY(U,$J,358.3,16485,2)
+106 ;;=^5001591
+107 ;;^UTILITY(U,$J,358.3,16486,0)
+108 ;;=D09.0^^61^775^44
+109 ;;^UTILITY(U,$J,358.3,16486,1,0)
+110 ;;=^358.31IA^4^2
+111 ;;^UTILITY(U,$J,358.3,16486,1,3,0)
+112 ;;=3^Carcinoma in Situ of Bladder
+113 ;;^UTILITY(U,$J,358.3,16486,1,4,0)
+114 ;;=4^D09.0
+115 ;;^UTILITY(U,$J,358.3,16486,2)
+116 ;;=^267742
+117 ;;^UTILITY(U,$J,358.3,16487,0)
+118 ;;=D06.9^^61^775^45
+119 ;;^UTILITY(U,$J,358.3,16487,1,0)
+120 ;;=^358.31IA^4^2
+121 ;;^UTILITY(U,$J,358.3,16487,1,3,0)
+122 ;;=3^Carcinoma in Situ of Cervix
+123 ;;^UTILITY(U,$J,358.3,16487,1,4,0)
+124 ;;=4^D06.9
